Class Actions Filed Against Unicycive, Nutex Health, LifeMD, and Snap.

Bragar Eagel & Squire, P.C. is reminding investors that class actions have been commenced on behalf of stockholders of Unicycive, Nutex Health Inc., LifeMD, Inc., and Snap, Inc. The lead plaintiff deadline for Unicycive is October 14, 2025. The complaints allege that defendants made false or misleading statements about the prospects of Unicycive's New Drug Application for oxylanthanum carbonate and the company's readiness to meet FDA manufacturing compliance requirements.

Investors in Unicycive Therapeutics, Inc. (NASDAQ: UNCY) are being urged to take action following the commencement of a class action lawsuit against the company. The lawsuit alleges that Unicycive made false and misleading statements regarding its readiness to meet FDA manufacturing compliance requirements and the regulatory prospects of its new drug application (NDA) for oxylanthanum carbonate.

The class action, filed by Pomerantz LLP, is on behalf of investors who purchased or otherwise acquired Unicycive securities between March 29, 2024, and June 27, 2025. The complaint alleges that during this period, Unicycive overstated its ability to satisfy the FDA's manufacturing compliance requirements and the regulatory prospects of its oxylanthanum carbonate NDA. These misrepresentations led to materially false and misleading public statements.

The lawsuit seeks to recover damages on behalf of those adversely affected by the alleged violations of the federal securities laws. Investors have until October 14, 2025, to request the Court appoint them as lead plaintiff in the class action. The ability to share in any recovery does not require serving as a lead plaintiff.

Unicycive is a clinical-stage biotechnology company that identifies, develops, and commercializes therapies to address unmet medical needs in the U.S. The company's stock price has been significantly impacted by recent FDA inspection findings and the issuance of a Complete Response Letter (CRL) for its oxylanthanum carbonate NDA.

Investors are encouraged to contact legal counsel to discuss their legal rights. Several law firms, including Pomerantz LLP, Faruqi & Faruqi, and The Gross Law Firm, are investigating claims against Unicycive and reminding investors to seek lead plaintiff status by October 14, 2025.

References:
[1] https://www.prnewswire.com/news-releases/pomerantz-law-firm-announces-the-filing-of-a-class-action-against-unicycive-therapeutics-inc-and-certain-officers--uncy-302538471.html
[2] https://www.ainvest.com/news/faruqi-faruqi-investigates-unicycive-therapeutics-securities-class-action-2508-97/
[3] https://www.marketscreener.com/news/investors-who-lost-money-on-unicycive-therapeutics-inc-uncy-should-contact-the-gross-law-firm-abo-ce7c50dfd089f621